Investor Relations Captor Therapeutics ®
Conclusion of the contract for the phasing of the CT-03 project
Publication date:
Publication time:
Date of drafting: 7 May 2024
Subject: Conclusion of the contract for the phasing of the CT-03 project
Legal basis: Article 17(1) MAR - confidential information.
The Management Board of Captor Therapeutics S.A., based in Wrocław, Poland (the "Company"), in reference to current report no. 55/2023 of 13 November 2023 and current report no. 7/2024 of 6 March 2024, announces that today it has concluded an agreement with the National Centre for Research and Development ("NCBR") for the funding of Phase II of the CT-03 project under the European Funds for the Modern Economy (FENG) programme (the "Agreement").
In accordance with the Agreement, the implementation of Phase II of the CT-03 project should be completed by 31.07.2026 at the maximum, while the amount of funding to be used from 1 January 2024, i.e. during the extended duration of the project, is PLN 4,976,940.75. The above deadline and amount are in line with motion filed by the Company, which the Company informed about in current report No. 55/2023 of 13 November 2023.
The Agreement contains standard provisions customary in NCBR public funding agreements.